Clinical Trial Update: Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene [Phase 1]

View source ↗

Summary

This clinical trial update discusses the safety and tolerability of intravitreal VG901 in patients with Retinitis Pigmentosa due to CNGA1 mutations, in a Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• VG901

Snippet

Sponsor: VeonGen Therapeutics GmbH | Conditions: Retinitis Pigmentosa | Phase 1 | Status: RECRUITING